

AMENDMENTS TO THE CLAIMS

1. – 14. (Canceled)

15. (Previously Presented) An isolated protein consisting of the amino acid sequence set forth in SEQ ID NO: 4.

16. (Previously Presented) A pharmaceutical composition, which comprises the protein of Claim 15 and one or more pharmaceutically acceptable additives.

17. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said one or more pharmaceutically acceptable additives is selected from the group consisting of a pH regulator, a buffer, a stabilizer, and a preservative.

18. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said protein is in an amount of 1 pg to 1 g.

19. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said composition is in a preparation form selected from the group consisting of an injection, an inhalant, a tablet, a granule, a powder, a capsule, and a suppository.

20. (Withdrawn) A method for searching for an agonist or an antagonist of an insulin receptor-related receptor binding by the protein of Claim 15, comprising:

contacting said insulin receptor-related receptor with said protein in the presence of a test substance,

measuring inhibition of the binding in the presence of the test substance, and

comparing binding of said protein in the presence of the test substance with binding of said protein in the absence of the test substance.

21. (Withdrawn) The method according to claim 20, wherein said measuring is obtained by surface plasmon resonance.

22. (Withdrawn) A method of regulating growth/differentiation in a cell which expresses an insulin receptor-related receptor comprising contacting said cell with the protein of Claim 15.

23. (Withdrawn) The method according to Claim 22, wherein the cell is a cell related to a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury.

24. (Withdrawn) The method according to Claim 23, wherein the cell is a pancreatic β cell.

25. (Withdrawn) The method according to Claim 22, wherein the protein is contained in a culture supernatant of rat glioma cells stimulated with a phorbol ester and concentrated in a fraction eluted with 8-20% acetonitrile from a C18 reverse phase HPLC column.

26. (Withdrawn) A method of regulating growth/differentiation in a cell which expresses an insulin receptor-related receptor comprising contacting said cell with the pharmaceutical composition of Claim 16.

27. (Withdrawn) The method according to Claim 26, wherein the cell is a cell related to a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury.

28. (Withdrawn) The method according to Claim 27, wherein the cell is a pancreatic β cell.

29. (Withdrawn) A method of treating a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of Claim 16.

30. (Withdrawn) The method according to Claim 29, wherein said effective amount ranges from 1 pg to 1 g per day.

31. (Currently Amended) An isolated protein, which has a binding activity to an insulin receptor-related receptor and the following characteristics:

(a) ~~it comprises~~ the protein comprises the amino acid sequence of SEQ ID NO: 4

(b) ~~it has~~ the protein has a molecular weight of about 6135, 6206, 6250 or 6321 measured by mass spectrometry using the Fourier transformation ion cyclotron method.

32. (Currently Amended) ~~A isolated~~ An isolated protein, which ~~has a binding activity~~ binds to an insulin receptor-related receptor, wherein the protein comprises an amino acid sequence selected from the group consisting of:

- an amino acid sequence of SEQ ID NO: 4,
- an amino acid sequence of SEQ ID NO: 3 ~~SEQ ID NO: 4~~ having an addition of an aspartic acid residue to the N-terminus and a deletion of a C-terminal aspartic acid residue,
- an amino acid sequence of SEQ ID NO: 5 ~~SEQ ID NO: 4~~ having an addition of an aspartic acid residue to the N-terminus,
- an amino acid sequence of SEQ ID NO: 6 ~~SEQ ID NO: 4~~ having an addition of an aspartic acid residue to the N-terminus and an addition of an alanine residue to the C-terminus, and
- an amino acid sequence of SEQ ID NO: 7 ~~SEQ ID NO: 4~~ having an addition of an alanine residue to the C-terminus.

33. (Previously Presented) A pharmaceutical composition, which comprises the protein of Claim 32 and one or more pharmaceutically acceptable additives.

34. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said one or more pharmaceutically acceptable additives is selected from the group consisting of a pH regulator, a buffer, a stabilizer, and a preservative.

35. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said protein is in an amount of 1 pg to 1 g.

36. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said composition is in a preparation form selected from the group consisting of an injection, an inhalant, a tablet, a granule, a powder, a capsule, and a suppository.

37. (Withdrawn) A method for searching for an agonist or an antagonist of an insulin receptor-related receptor binding by the protein of Claim 32, comprising:

contacting said insulin receptor-related receptor with said protein in the presence of a test substance,

measuring inhibition of the binding in the presence of the test substance, and

comparing binding of said protein in the presence of the test substance with binding of said protein in the absence of the test substance.

38. (Withdrawn) The method according to claim 37, wherein said measuring is obtained by surface plasmon resonance.

39. (Withdrawn) A method of regulating growth/differentiation in a cell which expresses an insulin receptor-related receptor comprising contacting said cell with the protein of Claim 32.

40. (Withdrawn) The method according to Claim 39, wherein the cell is a cell related to a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury.

41. (Withdrawn) The method according to Claim 40, wherein the cell is a pancreatic β cell.

42. (Withdrawn) The method according to Claim 40, wherein the protein is contained in a culture supernatant of rat glioma cells stimulated with a phorbol ester and concentrated in a fraction eluted with 8-20% acetonitrile from a C18 reverse phase HPLC column.

43. (Withdrawn) A method of regulating growth/differentiation in a cell which expresses an insulin receptor-related receptor comprising contacting said cell with the pharmaceutical composition of Claim 33.

44. (Withdrawn) The method according to Claim 43, wherein the cell is a cell related to a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury.

45. (Withdrawn) The method according to Claim 44, wherein the cell is a pancreatic β cell.

46. (Withdrawn) A method of treating a disease selected from the group consisting of diabetes, neuropathy, renal disorder, and gastrointestinal injury, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of Claim 33.

47. (Withdrawn) The method according to Claim 46, wherein said effective amount ranges from 1 pg to 1 g per day.

SUPPORT FOR THE AMENDMENTS

Claims 1-14 were canceled previously.

Claims 31 and 32 have been amended.

The amendment of Claims 31 and 32 is supported by original Claims 1 and 2, page 7, lines 25-26, Example 4 (page 30, line 14 to page 32, line 21), and the Sequence Listing as originally filed.

No new matter has been entered by the present amendment.